A Phase 1, Open-Label, Multiple-Dose, Drug-Drug Interaction Study (DDI) Evaluating Pharmacokinetics, Tolerability And Safety Of Glecaprevir Plus Pibrentasvir Co-administered With ELV/COBI/FTC/TAF (Genvoya) or DTG/ABC/3TC (Triumeq)

Trial Profile

A Phase 1, Open-Label, Multiple-Dose, Drug-Drug Interaction Study (DDI) Evaluating Pharmacokinetics, Tolerability And Safety Of Glecaprevir Plus Pibrentasvir Co-administered With ELV/COBI/FTC/TAF (Genvoya) or DTG/ABC/3TC (Triumeq)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Abacavir/dolutegravir/lamivudine; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Mar 2017 New trial record
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top